Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538116 · ClinicalTrials.gov registry record · Phase 2
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06538116: Active Phase 2 study of Alzheimer Disease, sponsored by Eli Lilly and Company.
NCT06538116 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 300 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06538116, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Primary Outcome
iADRS assesses the impact of cognitive loss on everyday activities and provides a measure of global AD severity as a single summary score. It comprises of 2 underlying domains "cognitive ability" and "functional ability," and integrates the items in both the domains a single overall score ranging from 0 to 144, with lower scores indicating worse performance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mevidalen
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Visionary Investigators Network - Aventura
- Excel Medical Clinical Trials, LLC Boca Raton dba Flourish Research - Boca Raton
- Vertex Clinical Research - Clermont
- Neuropsychiatric Research Center of Southwest Florida - Fort Myers
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Merritt Island Medical Research, LLC dba Flourish Research - Merritt Island
- Visionary Investigators Network - Miami
- Suncoast Clinical Research - New Port Richey - New Port Richey
- Renstar Medical Research - Ocala
- Charter Research, LLC - Orlando
- Progressive Medical Research - Port Orange
- Intercoastal Medical Group - Sarasota
- Brain Matters Research - Stuart
California
- Profound Research LLC At The Neurology Center of Southern California - Carlsbad
- Neuropain Medical Center - Fresno
- Catalina Research Institute - Montclair
- California Neuroscience Research, LLC - Sherman Oaks
Arizona
- Banner Alzheimer's Institute - Phoenix
Arkansas
- Baptist Health Center for Clinical Research LLC - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-08-26 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What the registry record for NCT06538116 still lists
NCT06538116 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06538116 names 20 study sites across 4 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06538116 about?
NCT06538116 is a clinical study titled "A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease". The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and...
What is the current status of trial NCT06538116?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2024-08-26. Estimated completion is 2026-05.
What conditions does trial NCT06538116 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06538116?
The interventions under investigation include: Placebo (DRUG), Mevidalen (DRUG).
Who is sponsoring clinical trial NCT06538116?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06538116 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06538116's enrollment target sits among peer trials
300 79th of 306 higher than 225 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI